Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PARMAX.BOthis companyParmax Pharma Limited	₹135.00	-2.83×	-1.91×	0.97×	-6.3×	-153.2%	18.4%	-38.4%	-34.3%	67.7%	-56.0%	-27.7%	-1.87×	-3.03×	-3.75×	0.74×	0.0%	—	—	1	D+
BERLDRG.BOBeryl Drugs Limited	₹25.49	22.95×	0.99×	0.5×	4.91×	-329.6%	28.6%	4.8%	2.2%	4.3%	5.2%	-5.3%	0.25×	0.89×	2.71×	1.52×	0.0%	5	3.87	1	C-
COLINZ.BOColinz Laboratories Limited	₹70.00	21.81×	1.12×	1.83×	7.57×	-17.6%	25.6%	4.1%	8.4%	5.1%	1.8%	28.8%	0.04×	-19.97×	5.39×	3.93×	0.0%	4	7.16	5	S-
DECIPHER.BODecipher Labs Ltd.	₹5.60	-1.71×	0.26×	0.38×	-1.49×	-90.6%	95.4%	-27.8%	-21.9%	-14.9%	-15.4%	-44.0%	0.02×	0.07×	0×	5.22×	0.0%	3	—	2	C
EMMESSA.BOEmmessar Biotech & Nutrition Limited	₹23.98	29.09×	1.56×	34.19×	-3.96×	-56.4%	-241.7%	-392.0%	117.6%	5.4%	-12.0%	5.1%	0×	5.41×	-581.48×	20.27×	0.0%	3	—	3	B-
EVOQ.BOEvoq Remedies Ltd.	₹1.60	-25.2×	0.14×	0.24×	-30.58×	-7336.2%	0.1%	-5.9%	-0.9%	-0.5%	-3.2%	-4.7%	0×	-0.34×	0×	6.77×	0.0%	3	1.82	2	B-
Peer median	—	21.81×	0.99×	0.5×	-1.49×	-90.6%	25.6%	-5.9%	2.2%	4.3%	-3.2%	-4.7%	0.02×	0.07×	0×	5.22×	0.0%	3	3.87	2	—